PhytoHealth

PHYTOHEALTH FOR BETTER LIFE

Products

R&D

Striving for excellence as the
leading botanical drug developer in Asia

PhytoHealth Corporation

Pipeline

「PG2 Lyo. Injection 500mg 」

Received “Orphan Drug Designation” status for treating Idiopathic thrombocytopenic purpura ( ITP) from FDA.

Extends its medical indication to treat stroke patients and be implemented the clinical trials by the stroke specialist in medical
center continually.

「PHN031」&「PHN033」

「PHN031」&「PHN033」were chosen to be the Cross-Strait Drug
Co-Development Projects. The CFDA’s Guidelines-compliant CMC(Chemistry, Manufacturing and Control )are underprepared.

「PHN031」

has completed US FDA Phase IIa clinical trials for the prevention of osteoporosis.

「PHN033」

has completed US FDA Phase IIa clinical trials for the treatment of diabetic nephropathy.

「PHN131」

「PHN131」for pain relief, has completed the pivotal clinical trials and statistical report . Submit to TFDA to apply New Drug Application on 2016.

NEWS

Medicine news
News
Media report

To read more news?

Investor

PhytoHealth Corporation

about phytohealth

CONTACT US

Dear visitor, If you have any questions about PhytoHealth
Please through the following Telephone service or feedback form to contact us：

+8862-25453697

PhytoHealth Corporation

5F., No.167, Fuxing N. Rd., Songshan Dist., Taipei City 105, Taiwan (R.O.C.)

follow
PhytoHealth Corporation © 2016 Phytohealth All rights reserved. Web Design - 好點子數位創意